1-3 of 3
Mark Cooper
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial

Free
Tu N. Nguyen, Katie Harris, Mark Woodward, John Chalmers, Mark Cooper, Pavel Hamet, Stephen Harrap, Simon Heller, Stephen MacMahon, Giuseppe Mancia, Michel Marre, Neil Poulter, Anthony Rogers, Bryan Williams, Sophia Zoungas, Clara K. Chow, Richard I. Lindley
Journal: Diabetes Care
Diabetes Care 2021;44(7):1622–1629
https://doi.org/10.2337/dc20-2664
Published: 25 May 2021
View articletitled, The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial
Open the PDF for The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial in another window
Journal Articles

Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial

Free
Jingyan Tian, Toshiaki Ohkuma, Mark Cooper, Stephen Harrap, Giuseppe Mancia, Neil Poulter, Ji-Guang Wang, Sophia Zoungas, Mark Woodward, John Chalmers
Journal: Diabetes Care
Diabetes Care 2020;43(6):1293–1299
https://doi.org/10.2337/dc19-1817
Published: 19 March 2020
View articletitled, Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial
Open the PDF for Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial in another window
Includes: Supplementary data
Journal Articles

Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial

Free
Yoichiro Hirakawa, Hisatomi Arima, Sophia Zoungas, Toshiharu Ninomiya, Mark Cooper, Pavel Hamet, Giuseppe Mancia, Neil Poulter, Stephen Harrap, Mark Woodward, John Chalmers
Journal: Diabetes Care
Diabetes Care 2014;37(8):2359–2365
https://doi.org/10.2337/dc14-0199
Published: 12 July 2014
View articletitled, Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial
Open the PDF for Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial in another window
Includes: Supplementary data